Literature DB >> 1423340

Naloxone or haloperidol but not yohimbine reverse apomorphine-induced respiratory depression.

J L Montastruc1, O Rascol, P Montastruc.   

Abstract

Intravenous injection of low doses of naloxone was found to reverse the respiratory depression induced by apomorphine in chloralose-anesthesized dogs. Similar results were obtained with haloperidol, whereas yohimbine remained ineffective. These data suggest that apomorphine depresses respiratory rate through a mechanism involving both dopamine and opiate mechanisms but not alpha 2-adrenoceptors. Respiratory arrest induced by overdosages of apomorphine can be treated with naloxone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423340     DOI: 10.1097/00002826-199210000-00009

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  5 in total

Review 1.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

2.  The effect of Yohimbine, an alpha2 adrenergic receptor antagonist, on the growth hormone response to apomorphine in normal subjects.

Authors:  S Lal; J X Thavundayil; B Krishnan; N P Nair; G Schwartz; H Guyda
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

3.  A study of tolerance to apomorphine.

Authors:  J L Montastruc; M E Llau; J M Senard; M A Tran; O Rascol; P Montastruc
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Naloxone does not prevent apomorphine-induced emesis or hypotension in dogs.

Authors:  J L Montastruc; M Lapeyre-Mestre; M E Llau; J M Senard; O Rascol; P Montastruc
Journal:  Clin Auton Res       Date:  1994-12       Impact factor: 4.435

Review 5.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.